Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Inclusion Criteria

- Patients with histologically documented, locally advanced or metastatic WD/DD liposarcoma who have received at least one prior systemic therapy - Patients with radiologic progression, defined by RECIST v.1.1, occurring while on/or within 6 months after last systemic treatment, prior to enrollment - ECOG performance status of 0-1

Exclusion Criteria

- Prior treatment with compounds with the same mode of action - Patients with TP53 mutated tumors, if the molecular status is known - Symptomatic central nervous system metastases - Inadequate organ function - Previous and concomitant therapy that precludes enrollment, as defined by protocol Other protocol-defined inclusion/exclusion criteria may apply.